Fibator EZ Tablet is a combination medication containing Atorvastatin (10mg), Fenofibrate (160mg), and Ezetimibe (10mg), designed to manage dyslipidemia and reduce cardiovascular risk by targeting multiple lipid parameters. Atorvastatin, a statin, works by inhibiting HMG-CoA reductase, thereby lowering LDL cholesterol and total cholesterol levels. Fenofibrate, a fibric acid derivative, primarily reduces triglycerides and increases HDL cholesterol by activating peroxisome proliferator-activated receptors (PPARs). Ezetimibe complements these effects by selectively inhibiting the absorption of cholesterol in the small intestine, further decreasing LDL cholesterol. The combined action of these agents provides comprehensive lipid control, making Fibator EZ effective for patients with mixed dyslipidemia or those who do not achieve target lipid levels with monotherapy. It is typically prescribed alongside lifestyle modifications such as diet and exercise. Patients should use this medication under medical supervision, as it may cause side effects including muscle pain, liver enzyme elevations, or gastrointestinal disturbances. Regular monitoring of lipid levels, liver function, and renal parameters is recommended during treatment. Fibator EZ Tablet offers a convenient and potent option for improving lipid profiles and reducing the risk of atherosclerosis and cardiovascular events.